Atlas Trials

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Clinical trial NCT02143726 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02143726
Sponsor
Alliance for Clinical Trials in Oncology
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory Hurthle Cell Thyroid Cancer
Start date
2014-10-09
Primary completion
2021-01-28
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.